Login / Signup

Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.

Youn Young ChoiMin-Kyoung KimHyeok Choon KwonGunn Hee Kim
Published in: Journal of Korean medical science (2021)
BNT162b2 vaccination was tolerable among adults who were ≥ 75 years of age.
Keyphrases
  • coronavirus disease
  • sars cov
  • community dwelling
  • physical activity
  • middle aged
  • respiratory syndrome coronavirus